Dual energy X-ray absorptiometry (DEXA) of the hip or spine has been shown to be an effective screening tool for osteoporosis in men undergoing androgen deprivation therapy (ADT) for advanced carcinoma of the prostate. A less expensive alternative to DEXA is the use of peripheral scanners, such as accuDEXA, which measures bone mineral density (BMD) the finger. In this paper, we reviewed 59 patients on ADT who underwent both accuDEXA scan of the non-dominant hand and DEXA scan of the hip. The mean T-scores calculated by the two techniques were similar; however, the individual T-scores correlated poorly with each other. We conclude that men who require ADT for prostate cancer should undergo standard DEXA of the hip for osteoporosis screening.
Introduction
Osteoporosis is being increasingly recognized in men who are on androgen deprivation therapy (ADT) for advanced carcinoma of the prostate (CAP). 1 Those who manage these patients are thus under increasing pressure to screen for this potential side effect in appropriate patients.
To date, the gold standard diagnostic technique for osteoporosis remains DEXA scanning of the hip. 2 Owing to the size, cost, maintenance and speed of hip DEXA scanning, a variety of peripheral technologies have been developed over the past few decades to make screening for osteoporosis more easily accessible. One such technology is accuDEXA. This portable device measures the BMD of the middle phalanx of the middle finger of the non-dominant hand and generates a T-score in a similar manner to hip DEXA. In previous studies, accuDEXA has been shown to strongly correlate with bone ash weight in cadaveric samples, 3 and has also been demonstrated to moderately correlate with standard hip DEXA in women with postmenopausal osteoporosis. 4 In this study, we compared accuDEXA with standard DEXA of the hip in men with locally recurrent, non-metastatic prostate cancer.
Methods
The charts of one urologist's (BSS) practice were retrospectively reviewed for patients who had failed primary therapy of localized prostate cancer (e.g. watchful waiting, radical prostatectomy and radiation therapy) as demonstrated by a rise in prostate specific antigen (PSA), and had been initiated on ADT. All patients had undergone accuDEXA testing in the office and subsequently underwent standard DEXA of the nondominant hip (Hologic QDR 4500 Delphi-C densimeter, Hologic Inc; Waltham, MA, USA; V 11.2 software). All DEXA scans were performed at the Coro Center bone density research facility at Rhode Island Hospital. Patients previously diagnosed with osteoporosis or with bony metastasis detected with bone scan were eliminated from the sample.
Results
Fifty-nine patients were eligible for the study. The mean age was 78.771.2 years and the mean duration of ADT was 3.470.3 years. The mean accuDEXA T-score was À2.2570.2 and the mean Hip DEXA T-score was À2.4370.2. The accuDEXA machine detected osteopenia and osteoporosis in 30 and 22 patients, respectively (50 and 36.7%, respectively), whereas the Hip DEXA detected osteopenia and osteoporosis in 34 and 22 patients, respectively (56.7 and 36.7%, respectively).
The mean T-scores of the two methods were not significantly different (À2.25 vs À2.43, P ¼ 0.2). However, linear regression analysis (Figure 1 ) of the T-scores generated by the two machines revealed a weakly linear correlation (R 2 ¼ 0.04), which was confirmed by Pearson (P ¼ 0.1) and Spearman (P ¼ 0.09) analyses. Similarly, linear regression analysis between the BMD values from each machine also demonstrated a weakly linear correlation (R 2 ¼ 0.1, data not shown). In order to visualize the nomograms built into the machines' internal databases of young, healthy normal male BMD values, the actual BMD values and respective T-scores from each patient were plotted against each other and graphed on the same set of axes ( Figure 2 ). The slopes of the two curves are noticeably different from each other (accuDEXA 0.06 vs Hip DEXA 0.13). Accordingly, the range of BMD that corresponds to a particular designation (e.g. osteopenia) is much narrower in the accuDEXA database than in the Hip DEXA database. This suggests that: (1) what is considered normal BMD occurs in a much narrower range in the phalanx; and (2) accuDEXA may significantly overestimate BMD at the hip.
Discussion
It is becoming increasingly recommended in the literature that men who are on ADT for advanced prostate cancer be screened for osteoporosis. The connection between ADT, usually achieved with luteinizing hormone-releasing hormone (LHRH) analogs such as leuprolide, and BMD is not entirely clear, but it is thought that the downregulation of both testosterone and estrogen has a negative effect on bone-anabolic osteoblastic activity. 1 Ever since the initial reports from the mid-1990s of osteoporosis as a complication of either orchiectomy or LHRH agonist therapy for CAP, 5, 6 numerous studies have confirmed that this is a real and distinct disease entity that needs to be addressed. 7 It has been estimated that in the United States at least a half million men with CAP have a rising PSA after primary therapy. 8 A large portion of those men will likely be treated with LHRH agonist therapy. As no randomized, prospective studies have been conducted, an accurate estimate of the incidence of ADT-induced osteoporosis is not well known; however, some retrospective studies have reported rates as high as 13%. 9 Even with more conservative estimates, this translates into an enormous cost, both in dollars and disease burden. For example, hip fracture carries with it a mortality rate of approximately 30% in men within the first year. 10 The screening for osteoporosis has largely been accomplished with DEXA of the hip or spine, which are generally considered the gold standard sites for diagnosis. Some proponents argue that the presence of osteoarthritis in the lumbar spine, particularly in the older population, render the hip the more preferable site. 11 Unfortunately, largely owing to its size, cost and maintenance needs, DEXA machinery is not widely available for population screening. Peripheral technologies such as accuDEXA have been developed to address this problem, but have not been clearly demonstrated to be effective screening modalities, particularly in patients who may be at increased risk for osteoporosis. Indeed, our data appear to suggest that the accuDEXA device may significantly overestimate hip BMD and under-diagnose osteoporosis. Figure 2 demonstrates what might account for the significant discrepancy between the T-scores generated by the accuDEXA and Hip DEXA machines. Nomograms generated from both machines' internal databases suggest that the range of normal BMD varies to a much larger degree in the hip than in the finger. Furthermore, this discrepancy underscores the fact that, although osteoporosis is a systemic disease, different areas of the skeleton are affected differently. For example, according to Figure 2 , a BMD of 0.700 g/cm 2 in the finger yields a normal T-score, whereas the same BMD in the hip translates into a borderline osteopenic-osteoporotic T-score. This could be attributed to the fact that the phalangeal bones are comprised of a higher ratio of cortical-to-trabecular bone compared to the femoral neck. We believe our findings emphasize the need to target screening methods to the region of highest clinical interest, in this case the hip. Although fractures of the fingers or other sites used in peripheral modalities are not clinically irrelevant, the consequences of hip fracture are far more significant. Until such peripheral technologies are optimized, or other methods of detecting osteoporosis of the hip are developed, it is our opinion that all men with CAP who require ADT undergo standard hip DEXA for osteoporosis screening. Diagnosis of osteoporosis in men on ADT DC Bae et al
Conclusions
Patients with advanced prostate cancer who require ADT should be screened for osteoporosis with DEXA of the hip. Peripheral modalities such as accuDEXA may not be sufficient to screen for osteoporosis because they may underestimate the results of hip DEXA, which we believe at this point most accurately estimates hip fracture risk.
